Company: INDP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001641172-25-023490
Chunk: 15

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 15
---
 all other classes and series of preferred stock at any time outstanding.

The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, may adversely affect the rights our common stockholders by, among other things:

| ● | restricting dividends on                                        
 the common stock;                                               |
| ● | diluting the voting power                                       
 of the common stock;                                            |
| ● | impairing the liquidation                                       
 rights of the common stock; or                                  |
| ● | delaying or preventing                                          
 a change in control without further action by the stockholders. |

As a result of these or other factors, the issuance of preferred stock could have an adverse impact on the market price of our common stock. There is no current intention for us to issue any shares of preferred stock.

Anti-takeover Effects of Certain Provisions of the Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws

General

The Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws contains provisions that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and that could make it more difficult to acquire control of us by means of a tender offer, open market purchases, a proxy contest or otherwise. A description of these provisions is set forth below.

Delaware Anti-Takeover Law

We are subject to Section 203 of the Delaware General Corporation Law. Section 203 generally prohibits a public Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:

| ● | prior to the date of the                                                                                                          
 transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted 
 in the stockholder becoming an interested stockholder;                                                                            |

| 9 |

| ● | upon consummation of the                                                                                                               
 transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of      
 the voting stock of the corporation outstanding at the time the transaction commenced, excluding specified shares; or                  |
| ● | at or subsequent to the                                                                                                                
 date of the transaction, the business combination is approved by the board of directors and authorized at an annual or special meeting 
 of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is